Dose-response relations were observed for death from hemato- and lymphopoietic cancers and from upper aerodigestive tract cancers, adjusting for age, time since first monitored, pay type, and external (gamma) radiation dose.
Accordingly, we conducted dose-response analyses for a) lung cancer (ICD-9 162); b) upper aerodigestive tract cancers encompassing the naso-oropharyngeal regions, esophagus, and stomach (ICD-9 140-151); c) hemato- and lymphopoietic cancers (ICD-9 200-208, excluding chronic lymphatic leukemias); d) urinary-tract cancers (ICD-9 188-189); and e) prostate cancer (ICD-9 185).
In dose-response analyses, monotonic associations were observed between cumulative internal dose and mortality from hemato- and lymphopoietic cancers and from cancers of the upper aerodigestive tract (Tables 4 and 5).
Other (non-ASL) cancer sites and types that may be connected with VC exposure include tumors of the liver (e.g., non-angiosarcoma), particularly hepatocellular carcinoma; respiratory system; digestive system other than the liver; lymphopoietic
and hematopoietic tissue; brain and other central nervous system; and malignant melanoma.
Total mortality White males (n = 15,539)(a) Cause of death Obs [SMR.sub.c] All causes of death 1,934 109(*) All malignant neoplasm 423 100 Respiratory system cancer 151 106 Central nervous system cancer - - Breast cancer 2 311 Thyroid cancer - - Leukemia 19 115 All other lymphopoietic
cancer 18 100 Nonmalignant respiratory disease 156 110 All heart disease 817 116(*) All external causes 156 109 Total mortality White females (n = 15,707(b) Cause of death Obs [SMR.sub.c] All causes of death 1,925 118(*) All malignant neoplasm 384 101 Respiratory system cancer 58 103 Central nervous system cancer - - Breast cancer 78 102 Thyroid cancer - - Leukemia 17 108 All other lymphopoietic
cancer 24 125 Nonmalignant respiratory disease 126 124(*) All heart disease 853 130(*) All external causes 61 109